DEF: TELA Bio Proposes Reverse Stock Split to Meet Nasdaq Requirements

TELA Bio, Inc. is holding a special meeting on October 8, 2026, to vote on a reverse stock split aimed at increasing its share price to comply with Nasdaq listing rules.

Summary

• TELA Bio, Inc. is holding a Special Meeting of Stockholders on October 8, 2026, to vote on a proposed reverse stock split.
• The reverse stock split aims to increase the per-share trading price of the company's common stock to meet Nasdaq's minimum bid price requirement of $1.00.
• The proposed ratio for the reverse stock split is between 1-for-5 and 1-for-15, with the exact ratio to be determined by the Board of Directors.
• The company received a deficiency letter from Nasdaq on March 17, 2026, regarding the bid price and is currently ineligible for an extended compliance period due to a stockholders equity deficiency.
• A second proposal is to approve the adjournment of the meeting if necessary to solicit additional votes for the reverse stock split proposal.
• The company's common stock closed at $0.79 on September 1, 2026, and $0.83 on the Record Date (September 8, 2026).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the company's precarious financial position and the necessity of a reverse stock split to maintain Nasdaq listing, indicating underlying business challenges.

Positives

• The virtual meeting format is intended to enable stockholders to attend and participate from any location at no cost, providing cost savings and reducing environmental impact.
• The reverse stock split, if successful, could potentially attract a broader range of investors, including institutional investors and brokerage firms, who may be reluctant to invest in lower-priced stocks.
• The Board believes a higher stock price may help generate investor interest in the Company.

Negatives

• The company is at risk of delisting from the Nasdaq Global Market due to not meeting the minimum bid price requirement ($1.00) for 30 consecutive business days.
• The company is also currently non-compliant with the stockholders equity requirement for listing on the Nasdaq Capital Market.
• Failure to approve the reverse stock split may lead to delisting and trading on less efficient over-the-counter markets, potentially impairing liquidity and investor access.
• There is no assurance that the reverse stock split will achieve the desired results or ensure continued listing on Nasdaq.
• The company may not be able to continue as a going concern if it cannot successfully raise sufficient additional capital.

Risks

• The reverse stock split may not result in an extended increase in the per-share price of common stock.
• There is no assurance that the market price per share will achieve the $1.00 minimum bid price requirement for a sufficient period for continued listing.
• The market price per share after the reverse stock split may not rise in proportion to the reduction in the number of shares outstanding.
• The reverse stock split may not attract brokers and investors who do not trade in lower-priced stocks.
• The reverse stock split could result in an increased proportion of unissued authorized shares, which could have possible anti-takeover effects.
• The company may not be able to continue as a going concern if it cannot raise sufficient additional capital.

Future Outlook

The company is exploring various sources of financing, including potential future sales of Common Stock or other securities. However, there is no assurance that any financing transaction would be undertaken or completed. If sufficient capital cannot be raised, the company may not be able to continue as a going concern.

Management Comments

• We believe that the virtual meeting format enables stockholders to attend and participate from any location around the world at no cost, provides for cost savings to TELA Bio, Inc. and our stockholders, and reduces the environmental impact of our Special Meeting.
• Your vote is important. Whether or not you plan to virtually attend the Special Meeting, we encourage you to vote as soon as possible to ensure that your shares are represented.
• Our primary objective in effectuating the Reverse Stock Split would be to attempt to raise the per-share trading price of our Common Stock to meet Nasdaqs listing requirements.
• Our Common Stock could be delisted from Nasdaq because shares of our Common Stock may continue to trade below the requisite $1.00 per share price needed to comply with the listing requirements of Nasdaq and maintain our listing.
• Our Board strongly believes that the Reverse Stock Split is necessary to support our compliance plan and to maintain our listing on Nasdaq.

Industry Context

StockSavvy.ai notes that reverse stock splits are often a measure taken by companies struggling to maintain exchange listing requirements, particularly for smaller biotechnology firms facing significant market pressures and funding challenges. This action by TELA Bio, Inc. is consistent with a broader trend among such companies seeking to improve their stock's market perception and meet minimum price thresholds.

Management Changes

Legal Proceedings

• The company received a deficiency letter from Nasdaq on March 17, 2026, regarding the closing bid price of its common stock not meeting the minimum requirement for continued listing on the Nasdaq Capital Market.
• The company is currently ineligible for an additional 180-day compliance period as it is also non-compliant with the stockholders equity requirement for listing on the Nasdaq Capital Market.

Stakeholder Impact

• Shareholders: Potential dilution if new shares are issued, risk of delisting impacting stock value and liquidity, potential for increased investor interest if reverse split is successful.
• Creditors: Risk to continued operations if capital is not raised, impacting ability to meet obligations.
• Employees: Potential impact on morale and ability to attract/retain talent if stock price remains low or delisting occurs.

Next Steps

• Stockholders will vote on the proposed reverse stock split at the Special Meeting on October 8, 2026.
• If approved, the Board of Directors will determine the exact ratio (between 1-for-5 and 1-for-15) and timing of the reverse stock split.
• The company plans to request a hearing with the Nasdaq Hearings Panel to submit a compliance plan for continued listing.
• The company will file a Form 8-K with the SEC within four business days following the Special Meeting to publish voting results.

Key Dates

Recommendation

The company is in a critical situation, facing potential delisting and going concern issues. While the reverse stock split is a necessary step to address Nasdaq listing requirements, its success is not guaranteed. The company's ability to raise capital is also uncertain. Given these significant risks, a 'hold' recommendation is appropriate, pending further clarity on the success of the reverse split and capital raising efforts.

Keywords

Reverse Stock Split, Nasdaq Listing, Special Meeting, Proxy Statement, Stockholder Approval, Bid Price Rule, Capital Raise, Going Concern